Dermata Corp (DRMA) - Long-Term Debt to Capital Coefficient

Dermata Therapeutics (DRMA) is implementing automated formula search and AI tissue modeling to develop dermatological agents. The company is deploying software robots to analyze clinical data sets, while this chart shows the market price is fixed at 0.00. The business relies on alliances with clinics to develop innovative drug delivery for rosacea and acne using microspheres.

This indicator determines the degree of the company's dependence on long-term debt financing relative to its equity. By analyzing the ratio of long-term liabilities to equity, an investor assesses the stability of the financial structure over a horizon of more than one year. The metric is calculated as the ratio of long-term loans to equity, identifying risks of excessive leverage. The stability of this balance is critical for Dermata Therapeutics (DRMA). This allows the company to seamlessly implement innovative microneedle platforms into the oversaturated acne treatment segment.